USMI will be using these funds to ramp-up manufacturing of its newly-released Canady Plasma XL-1000 SMART Electrosurgical Generator (XL-1000) and support the development and release of its Canady Helios Cold Plasma Generator and robotic delivery system for the selective treatment of cancer.
In April 2021, USMI completed the first FDA-IDE-approved clinical trial to evaluate cold atmospheric plasma for the treatment of cancer and is preparing for the launch of several Phase II multi-center international trials starting in 1Q23.
The company has recently released its new XL-1000 featuring Canady Hybrid Plasma Technology, a high-definition touchscreen, built-in surgical Apps, and a variety of safety and security features.
Hybrid Plasma electrosurgery technology is used in more traditional surgeries such as hip and knee replacements.
US Medical Innovations, LLC is a private US biomedical device company and wholly-owned subsidiary of US Patent Innovations, LLC.
USMI's focus is developing advanced innovative affordable plasma and robotic electrosurgical devices and striving to develop innovative devices in the field of plasma technology for the eradication of cancer.
Transgene announces promising data on investigational cancer vaccine TG4001
Servier announces results from vorasidenib Phase three INDIGO clinical trial
Nuvation Bio Forms Oncology-Focused Scientific Advisory Board
Report Looks at United States Vaccine Packaging Market 2023 - 2028
DELFI Diagnostics names new Vice President of Clinical Development
Sirnaomics doses first subject in phase one clinical trial of STP122G for anticoagulation treatment
Innovent Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
GSK Launches COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
AstraZeneca's Lynparza receives US approval for BRCA-mutated prostate cancer
Nykode Therapeutics expands clinical collaboration with Roche for advanced cervical cancer trial